CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


CNS PHARMACEUTICALS, INC. (CNSP): $3.03

-1.02 (-25.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNSP Stock Price Chart Interactive Chart >

Price chart for CNSP

CNSP Price/Volume Stats

Current price $3.03 52-week high $41.40
Prev. close $4.05 52-week low $2.87
Day low $2.87 Volume 122,005
Day high $4.05 Avg. volume 27,758
50-day MA $5.65 Dividend yield N/A
200-day MA $7.96 Market Cap 40.45M

CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET today. Beginning on November 29, 2022, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but

Yahoo | November 28, 2022

Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 results

CNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021.

Yahoo | November 15, 2022

CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended September 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.

Yahoo | November 14, 2022

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the first patient in Europe has been enrolled and dosed in France in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Yahoo | November 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Good morning, traders!

William White on InvestorPlace | October 24, 2022

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo -36.88%
3-mo -58.00%
6-mo -68.83%
1-year -90.98%
3-year -97.55%
5-year N/A
YTD -85.62%
2021 -60.54%
2020 -54.94%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6547 seconds.